Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4852151 | 0.84 | MCL1 (0.32) | MCL1 | |
| SCHEMBL7386654 | 0.76 | PSMB8 (0.33) | NPC1MAPTRAB9A | |
| SCHEMBL4850828 | 0.75 | — | — | |
| SCHEMBL4852140 | 0.69 | AHR (0.32) | — | |
| SCHEMBL4848591 | 0.68 | CYP3A4 (0.30) | TSHR | |
| SCHEMBL1778703 | 0.67 | HPGD (0.55) | ALDH1A1MAPTTSHR | |
| SCHEMBL4844097 | 0.65 | PSMB8 (0.38) | TP53MAPTSMN1; SMN2 | |
| SCHEMBL2382103 | 0.64 | PDK1 (0.40) | MAPT | |
| SCHEMBL1921514 | 0.63 | MAPT (0.46) | MCL1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL856111 | 0.63 | PRKCI (0.59) | MCL1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323488-B2 | Chromogenic enzyme substrates | BURTON MICHAEL | 2008-01-29 | — | — | US | claimed |
| EP-1436411-B1 | CHROMOGENIC ENZYME SUBSTRATES AND METHOD FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY | BURTON MICHAEL (GB) | 2005-12-14 | — | — | EP | claimed |
| US-20050124556-A1 | Chromogenic enzyme substrates | BURTON MICHAEL (GB) | 2005-06-09 | — | — | US | claimed |
| EP-1436411-A2 | CHROMOGENIC ENZYME SUBSTRATES AND METHOD FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY | Burton, Michael (GB) | 2004-07-14 | — | — | EP | claimed |
| WO-2003035896-A2 | CHROMOGENIC ENZYME SUBSTRATES AND METHOD FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY | BURTON MICHAEL (GB) | 2003-05-01 | — | — | WO | claimed |
| CN-116444523-A | Compounds as SMARCA2 inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-1980561-B1 | Substituted 1h-pyrazolo[3,4-b] pyridine derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-10-09 | — | — | EP | disclosed |
| EP-1980561-A1 | Substituted 1h-pyrazolo[3,4-b] pyridine derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2008-10-15 | — | — | EP | disclosed |
| US-7323488-B2 | Chromogenic enzyme substrates | BURTON MICHAEL | 2008-01-29 | — | — | US | disclosed |
| EP-1436411-B1 | CHROMOGENIC ENZYME SUBSTRATES AND METHOD FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY | BURTON MICHAEL (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20050124556-A1 | Chromogenic enzyme substrates | BURTON MICHAEL (GB) | 2005-06-09 | — | — | US | disclosed |
| EP-1436411-A2 | CHROMOGENIC ENZYME SUBSTRATES AND METHOD FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY | Burton, Michael (GB) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003035896-A2 | CHROMOGENIC ENZYME SUBSTRATES AND METHOD FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY | BURTON MICHAEL (GB) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124556-A1 | Chromogenic enzyme substrates | DCXR, MGAM, IDE | MCL1 2956/4885NPC1 4468/4885ALDH1A1 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.